Assessing the combined efficacy of Virechana,Kala Basti and Navaka Guggulu in managing Medoroga (Non- Alcoholic Fatty Liver Disease) - An Exploratory Study

Evaluate the combined efficacy of Virechana, Kala Basti and Navaka Guggulu in the management of Medoroga (Non- Alcoholic Fatty Liver Disease)- An Exploratory Study. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/077134

Enrollment

Registered

2024-11-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Socio-economic status-All 2. Diagnosed cases of Non-Alcoholic Fatty Liver Disease confirmed by USG (Upto grade 3) with or without symptoms of Non-Alcoholic Fatty Liver Disease. 3. AST, ALT Upto 120 U/L. 4. Patients willing to participate in the clinical trial. 5. Patients fit for Virechana and Basti Karma.

Exclusion criteria

Exclusion criteria: Patients with Uncontrolled diabetes mellitus (FBS more than 200 mg/dl), Uncontrolled Hypertension (BP more than 160/100 mmHg), Thyroid disorder. 2.Patients suffering from Hepatitis, Cirrhosis of liver, Ascites, Portal hypertension (PTH), patient having other chronic liver diseases and severely deranged LFT. 3. Patients having BMI less than 20 and more than 40. 4. Patients having deranged renal functions/chronic kidney diseases. 5. Patients suffering from AIDS, Tuberculosis and other infectious diseases. 6. Any Malignancy. 7. Pregnant and lactating women. 8. Patient on long term medication (Hepatotoxic medication like NSAID, Rifampicin,steroid). 9. Patients who are addicted to Alcohol or other narcotic substance. 10. Patients unfit for Virechana and Basti.

Design outcomes

Primary

Measure	Time frame
Changes in USG findings of Fatty liver (Grade 3/2/1 to Grade 2/1/0) along with reduction in the signs and symptoms of medoroga.Timepoint: Signs and symptoms of medoroga-0th Day, 29th Day, 59th Day and on follow up 90th Day. USG-0th Day and on follow up 90th Day	—

Secondary

Measure	Time frame
1. Significant changes in waist circumference. 2. Significant changes in Liver function tests. 3. Significant changes in Lipid profile. 4. Improvement in Quality Of Life of patients with NAFLD.Timepoint: 0th Day, 60th Day, 90th Day	—

Countries

India

Contacts

Public ContactDr Chaitali Vijay Lekurwale

All India Institute of Ayurveda, New Delhi

santoshbhatted@rediffmail.com9414048459

Outcome results